arrays were coupled to both the front-and back-surfaces of the crystal (DSR configuration). The spatial-, time-and energy-resolutions of both configurations were measured. Furthermore, two detector modules containing 4 BSR monolithic scintillator detectors each were mounted in a "table-top gantry" setup allowing the emulation of a full PET ring of arbitrary diameter using only 2 detectors in a stepand-shoot acquisition approach. Three-dimensional (3D) phantom images were acquired with both of the BSR detectors rotating at a radius of 35 cm from the center of the field-of-view. Results: In conventional BSR configuration, a detector spatial resolution of ~1.7 mm FWHM and a DOI resolution of ~3.7 mm FWHM was obtained, averaged over the entire detector area. In DSR configuration, a spatial resolution of ~1.1 mm FWHM was achieved in combination with a depth-of-interaction (DOI) resolution of ~2.4 mm FWHM. The energy resolution was ~10% in both detectors. The coincidence resolving time (CRT) in BSR and DSR configurations were ~215 ps FWHM and ~147 ps FWHM, respectively. Conclusions: Monolithic scintillator detectors based on dSiPMs are promising for PET applications in which high spatial resolution, TOF resolution, and detection efficiency are required, all at the same time. Compared to BSR, the DSR configuration significantly improves the time-, spatial-and DOI resolutions of the detector. At the conference, first images obtained with BSR detectors in a TOF-PET setup representative of a 70 cm diameter clinical scanner will be presented.
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Time Purpose: Proton minibeam radiotherapy aims to minimize normal tissue damage in the entrance channel while keeping tumor control through a homogeneous tumor dose due to channel widening with increasing track length. Side effects of proton minibeam irradiation were examined in an in-vivo mouse model to account for immune system, vasculature and higher complexity. Here, we report on our comparative study of minibeam and broad beam irradiation in the ear of Balb/c mice, to prove this hypothesis of reduced adverse effects in normal tissue. Methods: At the ion microprobe SNAKE, 20 MeV protons were administered to the right ear of 2-3 months old, female Balb/c mice, using an average dose of 60 Gy in a field of 7.2 x 7.2 mm2 in the central part of the ear, in two irradiation modes, homogeneous and minibeams. The 4 x 4 minibeams of 180 x 180 µm2 size were set in a distance of 1.8 mm, resulting in a dose of 6000 Gy in the channels, but with negligible dose in between. Inflammatory response, i.e. ear swelling and skin reactions were monitored for 90 days following irradiation, as well as genetic damage and release of inflammatory proteins. Results: No ear swelling or other skin reaction was detected after the minibeam irradiations, while significant ear swelling (up to 4-fold), erythema and desquamation (crust formation) developed in homogeneously irradiated ears 3-4 weeks after irradiation. Loss of hair follicles was only detected in the homogeneously irradiated fields after 4-5 weeks.
Conclusion: Our results prove that proton minibeam radiotherapy leads to reduced side effects compared to conventional broad beam irradiation and could become an option in clinical proton and/or heavy ion therapy. Purpose: The Local Effect Model (LEM) 1,2 and the Giant-Loop Binary-Lesion (GLOBLE) model 3 both are based on the analysis of DSB distribution within the cell nucleus and particularly focus on DNA lesion clustering properties with respect to the nanometer level as well as higher-order chromatin structure. According to this concept, radiation effects are uniquely determined by the number and microscopic spatial distribution of DSB. Here we demonstrate that this universal concept allows quantitative prediction of a wide variety of biological endpoints for different radiation qualities. Methods: Clustering on the nanometer level is considered on the level of SSB and leads to an increased yield of DSB as a consequence of interaction of two SSB induced in the DNA within a short distance. Clustering at the micrometer level is taken into account by the distinction of two DSB classes, depending on the number of DSB induced within chromatin loops of about 2 Mbp size: isolated DSB (iDSB) corresponding to exactly one DSB/loop, and clustered DSB (cDSB) corresponding to more than one DSB/loop. Predictions of biological effects are solely based on the yields of iDSB and cDSB, respectively. Results: For high-LET radiation, the concept allows predicting the observed increased relative biological effectiveness (RBE) and its dependence on the ion species, LET, dose and cell type 1,2 based on the knowledge of the corresponding photon dose response curves. Furthermore, the two classes of iDSB and cDSB can be identified with the two components leading to biphasic rejoining kinetics, and the model is able to correctly predict the fractions of fast and slow rejoining over a wide spectrum of different radiation qualities 4 . For high energetic photon radiation, the concept allows explaining the linear quadratic shape of the photon dose response curve and predicts a transition to a more linear shape at high doses 3 . The model also correctly reproduces dose rate effects after photon irradiation 5 . Furthermore the increased effectiveness of ultrasoft x-rays is predicted by the model as a consequence of the increased DSB yield 6 . Finally, based on the cell cycle dependent replication of chromatin loops the cell cycle dependent variation of radiosensitivity is reproduced. Based on the model parameters derived from normal cells, the different cell cycle dependent sensitivity of NHEJ-deficient and HRdeficient cells is predicted by the model 7 . Conclusion: Using the LEM and the GLOBLE model it could be shown that the knowledge of the initial spatial DSB distribution pattern induced by low-and high-LET radiation allows accurate quantitative prediction of radiation effects for a wide variety of different radiation qualities and biological endpoints. The consistent and simultaneous applicability of the model framework to widespread radiobiologic phenomena is a strong support for the underlying assumptions. Since some of the most modern ion therapy facilities are offering or considering the irradiation with alternative ion beams, beyond proton and carbon, it has raised new attention the need for a proper description of these beams, in order to exploit their use for specific applications. In particular, helium and oxygen beams are presently available in the research cave of the Heidelberg Ion therapy facility (HIT). We developed and integrated in TRiP98, our research treatment planning system, specific beam models for these ions, which have been validated experimentally on different levels. For the Helium beam a semiempirical model for dose deposition and fragmentation was implemented, by modification of algorithms conventionally used in space radiation transport studies, translated to the typical therapeutic range of energies [1] . For Oxygen beam, the standard transport model of TRiP98 was tuned on recent attenuation experiments and the fragmentation cascade has been improved using the latest beam models of the low-lying ions. Several treatment planning tests have been performed, showing no universal indications but rather selective advantages of the different beams, and revealing for example a considerable convenience of using Helium beams in specific configurations [2] , or proposing combination of different ions [3] . Experimental verification has been performed for both ion beams at the experimental room of HIT, analyzing different endpoints: basics physics data, delivered 3D physical dose distribution and biological effect. Monoenergetic and extended target irradiations of different extensions with single and double opposed fields have been verified. In the case of oxygen beams, considering that its main importance is related to a possible indication for partially hypoxic tumors, the biological verification was extended beyond the RBE weighted dose effect, but also including the OER effect. As previously obtained with carbon ions [4] , the kill-painting method, allowing to restore an homogeneous survival level on a differently oxygenated target, was verified with oxygen beams. It is found that with the latter ion beams, for a partially hypoxic target an inversion of the relative profile occurs, as compared to a normoxic case, with a slightly reduced normal tissue damage for same cell killing in the target than with the carbon irradiation. The demand for personalized medicine is increasing, and considering that the population suffering from chronic diseases (i.e. cancer, Alzeihmer) is continuously growing it is expected that the consumption of molecular diagnostic products and radiotherapeutics will continue to increase. In this scenario, TRIUMF and its fleet of proton accelerators ranging from 13 to 500 MeV is offering a unique environment for scientists to enable the production of isotopes with potential applications in molecular imaging or radiotherapy. A multidisciplinary program involving target design, isotope production and radiopharmaceutical chemistry has emerged in the Division of Life Sciences to facilitate and accelerate the translation from bench-to-bedside. A brief overview of the recent efforts related to the production and applications of medical isotopes at TRIUMF will be presented. Comprehensive studies have been conducted to improve the production of conventional PET isotopes by a better understanding of the physical phenomenon occurring inside the target during beam irradiation. Feasibility of the production, from liquid targets, of radiometals (i.e. 44 Sc, 68 Ga, 86 Y and 89 Zr) used in medical imaging has also been demonstrated. The results of the ITAP project, led by TRIUMF and including a consortium of institutions, on accelerator-based production of 99m Tc will be discussed. It has been shown that a reliable commercial scale (TBq) production of 99m Tc is achievable by using 100 Mo coated tantalum targets at energies up to 24 MeV. Investigations on the production and isolation of the therapeutic isotope 211 At and its imaging companion 209 At will be mentioned. Novel radiolabeling strategies and technologies have recently emerged to prepare radiopharmaceuticals and will be discussed. Isotopic exchange reactions are getting popular to rapidly and efficiently synthesize PET imaging probes. Click chemistry is also representing an attractive approach to radiolabel molecules because of its simple process, short reaction times and clean product synthesis. Microfluidic devices bear great promises in the field of radiochemistry as it is expected that they will allow faster reaction rate, exquisite reaction selectivity, reduced reagent consumption, and possibly revisit the hot-lab concept. An overview of the tracer development performed at TRIUMF (e.g. cysteine transporter, angiogenesis) will be presented. Finally, within the framework of the MEDICIS-PROMED consortium, a collaboration between TRIUMF and the Institute of Translational Molecular Imaging (ITMI) at the University Hospital of Geneva and the Laboratory of Bioorganic Chemistry and Molecular Imaging at EPFL will soon take place. This presentation will conclude with a short summary of our ambitious project on the development of dual modality molecular probes for ovarian cancer and their preclinical validations in animal models. 
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